NCT02966834 - Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis | Biotech Hunter

Enrollment

147

Participants

Timeline

Start Date

January 11, 2017

Primary Completion Date

April 15, 2020

Study Completion Date

April 15, 2020

Conditions

Cholestasis

Interventions

DRUG

Placebo

GSK2330672 matching placebo will be supplied as white film-coated tablets.

DRUG

GSK2330672

GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.

Trial Locations (66)

2050

GSK Investigational Site, Camperdown

3181

GSK Investigational Site, Prahran

4029

GSK Investigational Site, Herston

6009

GSK Investigational Site, Nedlands

10032

GSK Investigational Site, New York

11030

GSK Investigational Site, Manhasset

18104

GSK Investigational Site, Allentown

20142

GSK Investigational Site, Milan

20246

GSK Investigational Site, Hamburg

20900

GSK Investigational Site, Monza (MB)

28007

GSK Investigational Site, Madrid

28034

GSK Investigational Site, Madrid

33136

GSK Investigational Site, Miami

33604

GSK Investigational Site, Pessac

35128

GSK Investigational Site, Padua

38043

GSK Investigational Site, Grenoble

40138

GSK Investigational Site, Bologna

41013

GSK Investigational Site, Seville

46026

GSK Investigational Site, Valencia

48377

GSK Investigational Site, Novi

50134

GSK Investigational Site, Florence

59037

GSK Investigational Site, Lille

63003

GSK Investigational Site, Clermont-Ferrand

66421

GSK Investigational Site, Homburg

75571

GSK Investigational Site, Paris

85054

GSK Investigational Site, Phoenix

91054

GSK Investigational Site, Erlangen

95817

GSK Investigational Site, Sacramento

981104

GSK Investigational Site, Seattle

75390-8887

GSK Investigational Site, Dallas

T2N 4Z6

GSK Investigational Site, Calgary

T6G 2C8

GSK Investigational Site, Edmonton

R3E 3P4

GSK Investigational Site, Winnipeg

N6A 5A5

GSK Investigational Site, London

M5G 2C4

GSK Investigational Site, Toronto

H2X 0A9

GSK Investigational Site, Montreal

270-1694

GSK Investigational Site, Chiba

918-8503

GSK Investigational Site, Fukui

371-8511

GSK Investigational Site, Gunma

730-8619

GSK Investigational Site, Hiroshima

006-8555

GSK Investigational Site, Hokkaido

760-8557

GSK Investigational Site, Kagawa

252-0375

GSK Investigational Site, Kanagawa

856-8562

GSK Investigational Site, Nagasaki

545-8586

GSK Investigational Site, Osaka

591-8025

GSK Investigational Site, Osaka

105-8471

GSK Investigational Site, Tokyo

173-8606

GSK Investigational Site, Tokyo

181-8611

GSK Investigational Site, Tokyo

42-217

GSK Investigational Site, Częstochowa

40-506

GSK Investigational Site, Katowice

41-400

GSK Investigational Site, Mysłowice

00-332

GSK Investigational Site, Warsaw

50-349

GSK Investigational Site, Wroclaw

08036

GSK Investigational Site, Barcelona

RG24 9NA

GSK Investigational Site, Basingstoke

B15 2GW

GSK Investigational Site, Edgbaston

G31 2ER

GSK Investigational Site, Glasgow

L7 8XP

GSK Investigational Site, Liverpool

NW3 2QG

GSK Investigational Site, London

M13 9WU

GSK Investigational Site, Manchester

TS4 3BW

GSK Investigational Site, Middlesbrough

NE1 4LP

GSK Investigational Site, Newcastle upon Tyne

NG7 2UH

GSK Investigational Site, Nottingham

PL6 8DH

GSK Investigational Site, Plymouth

S5 7AU

GSK Investigational Site, Sheffield